Clinical Trials Logo

Pneumonia, Pneumococcal clinical trials

View clinical trials related to Pneumonia, Pneumococcal.

Filter by:

NCT ID: NCT01444001 Completed - Clinical trials for Pneumococcal Infections

Study of an Investigational Pneumococcal Vaccine in Healthy Adult Volunteers

Start date: February 2007
Phase: Phase 1
Study type: Interventional

This study was designed to evaluate the safety, tolerability, and immunogenicity of three doses of an investigational pneumococcal vaccine in healthy adult volunteers. Primary Objective: - To evaluate the safety and tolerability of an investigational Pneumococcal vaccine.

NCT ID: NCT01402245 Completed - Clinical trials for Pneumococcal Pneumonia

Targeting of Immune Response After Pneumococcal Vaccination

PncHR
Start date: January 2005
Phase: Phase 4
Study type: Interventional

Pneumococcal polysaccharide vaccine does not confer protection against noninvasive pneumonia. The study aims to compare lymphocyte homing in pneumonia and in those receiving Pnc polysaccharide vaccine (PPV) or Pnc conjugate vaccine (PCV)

NCT ID: NCT01086397 Completed - Clinical trials for Pneumonia, Pneumococcal

Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US With Community-Acquired Pneumonia

Start date: February 2010
Phase: N/A
Study type: Observational

The main purpose of this study is to use an investigational urine assay to estimate the proportion of pneumonia in adults 50 years or older in different areas throughout the US that is caused by certain types of the bacteria Streptococcus pneumoniae (also called pneumococcus).

NCT ID: NCT01028326 Active, not recruiting - Clinical trials for Pneumococcal Pneumonia

PCV10 Reactogenicity and Immunogenicity Study - Malindi

PRISM
Start date: January 2010
Phase: Phase 4
Study type: Interventional

The World Health Organization has recommended that developing countries should incorporate pneumococcal conjugate vaccine (PCV) into their routine immunization schedules. The Kenya Ministry of Health anticipates introducing a new formulation of PCV, PCV10, into the routine childhood immunization schedule in 2010. In the areas of Kenya that have been designated to monitor the impact of vaccine, a catch-up campaign will be implemented to vaccinate children aged 12-59 months. PCV10 has been found to be safe and effective in infants. It is licensed for use in children up to 2 years of age, but its use as a primary series in children over age 12 months has not been evaluated. This study will assess the immunogenicity and reactogenicity of PCV10 first administered at an age of 12-59 months.

NCT ID: NCT00744263 Completed - Clinical trials for Pneumococcal Infections

Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults

CAPITA
Start date: September 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate vaccine in the prevention of the first episode of vaccine-type pneumococcal community-acquired pneumonia in adults.

NCT ID: NCT00429975 Terminated - Clinical trials for Pneumonia, Pneumococcal

Ceftriaxone Vs Levofloxacin on Cytokine Expression in Pneumococcal Pneumonia

Start date: August 2004
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare levofloxacin vs ceftriaxone impact on the cytokine production in patients with pneumococcal pneumonia.

NCT ID: NCT00035269 Completed - Clinical trials for Gram-positive Bacterial Infections

New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)

Start date: December 2001
Phase: Phase 3
Study type: Interventional

This study will treat patients who have a community-acquired pneumonia that is due to a specific bacteria (S. pneumoniae)